Tvardi Therapeutics' TTI-109 Phase 1 study confirms prodrug design, improved tolerability, and STAT3 target engagement

Tvardi Therapeutics, Inc.

TTI-109 rapidly converted to TTI-101 within 2 hours, achieving equivalent plasma exposure at molar-equivalent doses.
Diarrhea duration with TTI-109 was 0.46 days vs 3.35 days for TTI-101; similar to placebo.
Pharmacodynamic data showed up to 60% reductions in STAT3-driven immune cell populations (Th17, Tfh, B cells).
Company plans to advance TTI-109 into STAT3-driven dermatologic and GI diseases, subject to additional funding.
No serious adverse events; one discontinuation due to transaminitis deemed unlikely related.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.